Data Supporting the Potential Use of Rusfertide Therapy in Hereditary Hemochromatosis

Protagonist Therapeutics Announces Positive Phase 2a Data Supporting the Potential Use of Rusfertide as a First-in-Class Therapy in Hereditary Hemochromatosis | Protagonist Therapeutics, Inc.
https://investors.protagonist-inc.com/news-releases/news-release-details/protagonist-therapeutics-announces-positive-phase-2a-data/